The U.S. still lacks clinical guidelines for diagnosing and treating adult ADHD, leaving many adults undiagnosed and untreated. Experts are now working to address this gap.
The Company is currently developing CYB003, a proprietary deuterated psilocin program, about to enter Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004 ... as “may”, ...